 Naltrexone
"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.549.686.750.550 D03.605.497.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
Celupan- Celupan
- Lacer Brand of Naltrexone Hydrochloride
ReVia- ReVia
- Schering-Plough Brand of Naltrexone Hydrochloride
- Schering Plough Brand of Naltrexone Hydrochloride
- Lamepro Brand of Naltrexone Hydrochloride
- United Drug Brand of Naltrexone Hydrochloride
- Orphan Brand of Naltrexone Hydrochloride
- Nemexin
- Bristol-Myers Squibb Brand of Naltrexone Hydrochloride
- Bristol Myers Squibb Brand of Naltrexone Hydrochloride
- Du Pont Brand of Naltrexone Hydrochloride
- Nalorex
Antaxone- Antaxone
- Pharmazam Brand of Naltrexone Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in UAMS Profiles by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 2 | 2 | | 2021 | 1 | 1 | 2 | | 2020 | 1 | 1 | 2 | | 2019 | 1 | 0 | 1 | | 2018 | 3 | 1 | 4 | | 2016 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2014 | 2 | 0 | 2 | | 2013 | 2 | 0 | 2 | | 2012 | 1 | 0 | 1 | | 2011 | 0 | 2 | 2 | | 2010 | 3 | 0 | 3 | | 2009 | 1 | 1 | 2 | | 2008 | 3 | 1 | 4 | | 2006 | 2 | 1 | 3 | | 2005 | 6 | 1 | 7 | | 2004 | 4 | 0 | 4 | | 2003 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles over the past ten years.
-
Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2022 10 01; 79(10):981-992.
-
Obeng S, Leon F, Patel A, Zuarth Gonzalez JD, Chaves Da Silva L, Restrepo LF, Gamez-Jimenez LR, Ho NP, Guerrero Calvache MP, Pallares VLC, Helmes JA, Shiomitsu SK, Soto PL, McCurdy CR, McMahon LR, Wilkerson JL, Hiranita T. Interactive Effects of ?-Opioid and Adrenergic-a2 Receptor Agonists in Rats: Pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and Its Metabolite 7-Hydroxymitragynine. J Pharmacol Exp Ther. 2022 12; 383(3):182-198.
-
Berquist MD, Fantegrossi WE. Effects of 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine on alcohol consumption in Long-Evans rats. Behav Pharmacol. 2021 08 01; 32(5):382-391.
-
Woody GE, Poole S, Yu E, Carroll J, Lynch KG. Extended release injectable naltrexone before vs. after release: A randomized trial of opioid addicted persons who are in prison. J Subst Abuse Treat. 2021 08; 127:108355.
-
Mitchell MM, Schwartz RP, Choo TH, Pavlicova M, O'Grady KE, Gryczynski J, Stitzer ML, Nunes EV, Rotrosen J. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis. Drug Alcohol Depend. 2021 02 01; 219:108422.
-
Saunders EC, Moore SK, Walsh O, Metcalf SA, Budney AJ, Scherer E, Marsch LA. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders. J Subst Abuse Treat. 2020 04; 111:54-66.
-
Elton A, Dove S, Spencer CN, Robinson DL, Boettiger CA. Naltrexone Acutely Enhances Connectivity Between the Ventromedial Prefrontal Cortex and a Left Frontoparietal Network. Alcohol Clin Exp Res. 2019 05; 43(5):965-978.
-
Maggio SE, Saunders MA, Nixon K, Prendergast MA, Zheng G, Crooks PA, Dwoskin LP, Bell RL, Bardo MT. An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic a6?2* antagonist r-bPiDI. Drug Alcohol Depend. 2018 12 01; 193:154-161.
-
Lovallo WR, Acheson A, Vincent AS, Sorocco KH, Cohoon AJ. Early life adversity diminishes the cortisol response to opioid blockade in women: Studies from the Family Health Patterns project. PLoS One. 2018; 13(10):e0205723.
-
Yadlapalli JSK, Bommagani SB, Mahelona RD, Wan A, Gannon BM, Penthala NR, Dobretsov M, Crooks PA, Fantegrossi WE. Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-O-sulfate in rats: Drug discrimination and physical dependence. Pharmacol Res Perspect. 2018 07; 6(4):e00403.
-
Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, Seal D. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018 11; 86:104-110.
-
Tanda G, Mereu M, Hiranita T, Quarterman JC, Coggiano M, Katz JL. Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids. Neuropsychopharmacology. 2016 10; 41(11):2772-81.
-
Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016; 35(1):22-35.
-
Helton SG, Lohoff FW. Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. Psychiatry Res. 2015 Dec 15; 230(2):121-9.
-
Lovallo WR, Enoch MA, Acheson A, Cohoon AJ, Sorocco KH, Hodgkinson CA, Vincent AS, Glahn DC, Goldman D. Cortisol Stress Response in Men and Women Modulated Differentially by the Mu-Opioid Receptor Gene Polymorphism OPRM1 A118G. Neuropsychopharmacology. 2015 Oct; 40(11):2546-54.
-
Murphy BL, Ravichandran C, Babb SM, Cohen BM. Naltrexone in bipolar disorder with depression: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014 Dec; 34(6):749-51.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|